ESI Group, in Collaboration With ENSAM, Deploys in Open Source Its "Inspector" Software
3.5.2022 15:00:00 EEST | Business Wire | Press release
Regulatory News:
ESI Group (ISIN Code: FR0004110310, Mnemo: ESI), a global simulation and virtual prototyping software partner for industry, announces the open-source release of its Inspector software; an opening for the scientific community, industrial collaboration, and innovation.
Inspector is a visual and interactive data exploration software that can analyze a large volume of data to extract useful information that can be applied in the following contexts: predictive maintenance, cybersecurity, control, and analysis of machine learning algorithms.
By making Inspector software available to as many people as possible, ESI Group continues its commitment to the industrial and academic ecosystems, offering them the possibility of working on a reliable and customizable solution to meet the technical challenges and specific needs of the community.
ENSAM (Ecole Nationale Supérieure d'Arts et Métiers) will lead the development and expansion of Inspector, as part of the continuum of sponsorship and co-creation activities already in progress between ESI Group and ENSAM. This collaboration has been reinforced with their mutual involvement in the DesCartes program led by the CNRS in Singapore, the CREATE-ID international research chair, and through the ESI - ENSAM virtual engineering laboratory.
This open-source approach has many advantages. First, it allows the community to use the software in an optimal and fast way, thus, enabling the scientific community to benefit from new functionalities adapted to the requirements of each user, as well as from security improvements. Secondly, through its approach, ESI Group wishes to offer an opportunity to benefit from a software whose reliability has been proven over the years by its customers in various industries, including Automotive and Aeronautics. “Inspector” will continue to evolve and adapt to the needs of the community thanks to the collaboration of the numerous stakeholders.
Several industry players and “Inspector” users have expressed interest and support for ESI Group's initiative to deploy its data analysis software in open source. This is the case, for example, with CNS.
Stephane Perrin, Managing Director of CNS states: "The decision taken by ESI Group is a great illustration of the Group’s dedication to the innovation and scientific ecosystem with its cutting-edge technologies. At CNS, a Network and Security expertise company, we are mobilized to ensure the future of Inspector. In addition to integrating Inspector into our continuous network auditing software suite, we will also soon offer support for the software via our business unit dedicated to innovative solutions."
Emmanuel Leroy, EVP Product, Innovation & Industry Solutions at ESI Group said: "Data and open source are the two main keywords of this new coordinated action with ENSAM. We are delighted to be able to take our collaboration a step further while contributing to academic and industrial research and innovation. "Inspector" will provide users with a tool for analyzing large volumes of data to optimize the performance of manufacturing processes. In a period where data is becoming key but remains expensive; I am convinced that this open-source release will open opportunities for industrial players, whether they are large companies or startups."
Information on how to obtain the Inspector download and installation links
The "Inspector" module can be retrieved as an archive (674MB) with the following command: sftp inspector@jibleo.com:source_code/inendi-inspector_opensource_export_2022-01-27.tgz.
The password associated with the SFTP account "inspector" is "ut!iep2E" and the checksum sha256 of the archive is d0404dd13c80ec8a4e32f406986731025881097ed03fa47a4af77827744f1000
The location of the Gitlab project from which the export was made is the following: https://gitlab.com/inendi/inspector
The software can now be installed with the following command (as indicated in the documentation on the Gitlab project homepage): flatpak install --user -y https://inendi.gitlab.io/inspector/install.flatpakref
About ESI Group
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation. Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high-level specialists around the world and reported 2021 sales of €136.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com.
Follow ESI: LinkedIn | Facebook | Twitter | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005291/en/
Contact information
ESI - Press
Florence Barré
press@esi-group.com
+33 1 49 78 28 28
Verbatee – Press Relations
Jérôme Goaer, j.goaer@verbatee.com, +33 6 61 61 79 34
Aline Besselièvre, a.besselievre@verbatee.com, +33 6 61 85 10 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
